Company Overview - Beijing RMT Medical Technology Co., Ltd. was established in 2001 and successfully listed on the Shenzhen Stock Exchange's Growth Enterprise Market on November 1, 2022 [2] - The company specializes in providing comprehensive treatment solutions for OSA and COPD patients, focusing on home non-invasive ventilators and ventilation masks [2] - RMT is the first domestic company to have non-invasive ventilator products certified by the FDA, with sales in over 100 countries [2] Research and Development - As of December 31, 2024, the company holds 633 valid patents in China, including 107 invention patents, 390 utility model patents, and 136 design patents [3] - The company also has 202 valid overseas patents, including 39 in the United States and 30 in Europe [3] Financial Performance - In Q1 2025, the company's overseas revenue reached 170 million CNY, a year-on-year increase of 35.48%, while domestic revenue was 96 million CNY, with a quarter-on-quarter growth of 48.79% and a year-on-year growth of 43.03% [4] - The gross margin for domestic operations was 51.51%, and for overseas operations, it was 48.47%, with both showing an increase compared to the previous quarter [4] Product Launches and Market Strategy - The newly launched P5 series ventilators are primarily targeted at domestic hospital channels, which have a relatively high gross margin [4] - The introduction of the RMT oxygen bottle marks a strategic shift towards the consumer goods market, enhancing brand influence and market share [5] Brand Development - The company's rebranding to "RMT" signifies a strategic alignment between product and capital markets, aiming to enhance brand value [5] - The name "RMT" reflects the company's commitment to respiratory health and smart technology, creating a unified identity across products and capital markets [5] Market Expansion - The company has made adjustments to domestic channel policies and sales strategies, resulting in improved revenue and gross margins in Q1 2025 [5] - In Europe, the company has completed the construction of its cloud platform and is onboarding agents, laying the groundwork for future growth in the mainstream medical insurance market [5]

Group 1: Company Overview - Beijing Ruimait Medical Technology Co., Ltd. was established in 2001 and launched its first multi-channel sleep monitor in 2003, followed by the first CPAP sleep machine in 2007 [2] - The company focuses on providing comprehensive treatment solutions for OSA and COPD patients, covering diagnosis, treatment, and chronic disease management [2] - Ruimait is a leading domestic company in non-invasive ventilators and masks, being the first domestic company to receive FDA certification for non-invasive ventilators [2][3] Group 2: Market Position and Performance - As of 2023, Ruimait holds a 30.6% market share in the domestic market for home non-invasive ventilators, ranking first, and a 12.4% share globally, ranking second [4] - The company has established a comprehensive product line, including home non-invasive ventilators, masks, sleep monitors, high-flow humidified oxygen therapy devices, and oxygen concentrators [2][3] Group 3: Research and Development - As of December 31, 2024, the company holds 633 valid patents in China, including 107 invention patents, 390 utility model patents, and 136 design patents [3] - The company also has 202 valid overseas patents, including 39 in the United States and 30 in Europe [3] Group 4: Strategic Initiatives - The recent rebranding to "Ruimait" aims to unify product identity and capital market recognition, enhancing brand value and market penetration [5] - A strategic partnership with Shenzhen Hanyu Pharmaceutical Co., Ltd. focuses on joint development of respiratory machines and health products, targeting mild sleep disorder consumers [6] - The company is exploring collaboration with Qiangnao Technology, a leader in non-invasive brain-machine interfaces, to enhance product functionality [7] Group 5: Financial Performance and Market Strategy - In Q1 2025, the company reported an increase in domestic business revenue and gross margin, indicating a stable market performance [8] - The launch of the Ruimait oxygen bottle signifies a strategic shift towards consumer products, aiming to enhance brand influence and market share [10]